Newsroom
Updates about Leica Biosystems.
Expansion of the Aperio AI Store gives researchers more ways to study cancer through AI-enabled tools within a connected digital pathology ecosystem VISTA, Calif., SEPTEMBER 24, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions,…
HistoCore LIGHTNING C Laser Cassette Printer helps laboratories improve specimen identification and tracking while reducing costs DEER PARK, Ill., SEPTEMBER 16, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, reinforces its…
Portfolio expansion marks new era for diagnosis delivery, translating digital pathology innovation to clinical impact by accelerating workflows and patient care VISTA, Calif., August 11, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology…
DEER PARK, Ill. – July 14, 2026 – Leica Biosystems, an operating company of Danaher (the “Company”), and a global leader in anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has entered into a definitive agreement to acquire privately held StatLab…
Leveraging trusted automation from Leica Biosystems, the new offering helps researchers move from tissue sample to biological insight faster through more flexible, higher-plex immunofluorescence LOS ANGELES, CA — June 25, 2026 — Molecular Instruments® (MI), founded by the inventor of HCR™…
Milestone deployment reflects growing demand for high-throughput, AI-enabled digital pathology workflows VISTA, CA, June 24, 2026 – Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Versant Diagnostics, an independent physician…
[DEER PARK, Ill. — June 9, 2026] — Leica Biosystems, a Danaher company and a global leader in end to end anatomic and digital pathology solutions, is advancing how pharmaceutical organizations scale digital and computational pathology to support AI enabled biomarker discovery and companion…
Designed to adapt to diverse biopharma development needs, and enabled by close collaboration and parallel execution, the partnership introduces a flexible global framework for companion diagnostic development intended to support more efficient progression from early-stage assays to commercial…
The Danaher company expands its collaboration with AstraZeneca and Daiichi Sankyo to develop an end-to-end system for TROP2 NMR in non-small cell lung cancer Newcastle, United Kingdom — May 29, 2026 — Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital…